GÃ¡bor Halmos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11291953/publications.pdf

Version: 2024-02-01

95 papers	3,570 citations	94433 37 h-index	155660 55 g-index
96 all docs	96 docs citations	96 times ranked	1724 citing authors

#	Article	IF	Citations
1	Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides, 2022, 150, 170716.	2.4	7
2	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches. Molecules, 2022, 27, 2671.	3.8	4
3	Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates. International Journal of Molecular Sciences, 2022, 23, 5071.	4.1	6
4	Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer. Molecules, 2021, 26, 1253.	3.8	2
5	Hypothalamic Releasing Hormones. , 2020, , 43-68.		1
6	Correlation between the Expression of Angiogenic Factors and Stem Cell Markers in Human Uveal Melanoma. Life, 2020, 10, 310.	2.4	3
7	Expression of Somatostatin Receptor Subtypes (SSTR-1â€“SSTR-5) in Pediatric Hematological and Oncological Disorders. Molecules, 2020, 25, 5775.	3.8	4
8	Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy. DNA Repair, 2019, 84, 102642.	2.8	28
9	Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers. International Journal of Molecular Sciences, 2019, 20, 5027.	4.1	8
10	Novel Crizotinibâ€“GnRH conjugates revealed the significance of lysosomal trapping in GnRH-based drug delivery systems. International Journal of Molecular Sciences, 2019, 20, 5590.	4.1	5
11	Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification. Pharmaceutics, 2018, 10, 223.	4.5	21
12	Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicinâ€“GnRH-III conjugates developed for targeted drug delivery. Beilstein Journal of Organic Chemistry, 2018, 14, 756-771.	2.2	19
13	Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines. OncoTargets and Therapy, 2018, Volume 11, 933-941.	2.0	5
14	Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). European Journal of Pharmaceutical Sciences, 2018, 123, 371-376.	4.0	4
15	Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma. Molecules, 2018, 23, 1535.	3.8	4
16	Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma. Oncology Reports, 2017, 37, 1927-1934.	2.6	6
17	Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e21-533.e27.	1.6	45
18	Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1641-1649.	2.5	8

#	Article	IF	Citations
19	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2617-2622.	7.1	27
20	Novel antagonists of growth hormoneâ€releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer, 2012, 118, 670-680.	4.1	31
21	Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3755-3760.	7.1	69
22	GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle, 2009, 8, 3149-3156.	2.6	37
23	Doseâ€dependent growth inhibition in vivo of PCâ€3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZâ€Jâ€7â€138. Prostate, 2008, 68, 1763-1772.	2.3	31
24	Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs, 2008, 19, 349-358.	1.4	19
25	Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1943-1946.	7.1	39
26	Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18671-18676.	7.1	32
27	The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDAâ€PCaâ€2b and LuCaPâ€35 prostate cancers. Prostate, 2007, 67, 1339-1353.	2.3	19
28	Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology, 2006, 29, 463.	3.3	1
29	Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate, 2006, 66, 200-210.	2.3	15
30	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer, 2006, 118, 222-229.	5.1	26
31	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14513-14518.	7.1	33
32	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10403-10407.	7.1	40
33	Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4610-4615.	7.1	22
34	Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Suizo, 2006, 21, 384-386.	0.1	0
35	Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology, 2006, 29, 463-9.	3.3	0
36	Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs, 2005, 16, 159-165.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog. Pancreas, 2005, 31, 275-282.	1.1	22
38	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer, 2005, 104, 1312-1321.	4.1	39
39	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. Cancer, 2005, 104, 2266-2274.	4.1	17
40	Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate, 2005, 64, 303-315.	2.3	42
41	Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrine-Related Cancer, 2005, 12, 999-1009.	3.1	36
42	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10628-10633.	7.1	21
43	The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17424-17429.	7.1	110
44	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkinâ€™s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer, 2005, 41, 2196-2202.	2.8	31
45	Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Letters, 2005, 226, 123-131.	7.2	16
46	Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15160-15165.	7.1	24
47	Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1708-1713.	7.1	41
48	Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238. Journal of Urology, 2004, 171, 911-915.	0.4	21
49	Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer, 2003, 98, 1401-1410.	4.1	42
50	Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9512-9517.	7.1	61
51	Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 196-200.	7.1	73
52	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4707-4714.	3.6	71
53	Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 961-965.	7.1	30
54	Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. International Journal of Cancer, 2002, 98, 624-629.	5.1	28

#	ARTICLE	IF	CITATIONS
55	Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anti-Cancer Drugs, 2001, 12, 761-768.	1.4	54
56	Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer, 2001, 92, 1168-1176.	4.1	23
57	Hypothalamic Hormones and Cancer. Frontiers in Neuroendocrinology, 2001, 22, 248-291.	5.2	235
58	Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2144-2152.	3.6	51
59	Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. , 2000, 88, 1384-1392.		28
60	Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate, 2000, 42, 295-303.	2.3	150
61	Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate, 2000, 44, 172-180.	2.3	60
62	Peptide analogs in the therapy of prostate cancer. Prostate, 2000, 45, 158-166.	2.3	109
63	Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Research and Treatment, 2000, 59, 255-262.	2.5	33
64	Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Research and Treatment, 2000, 60, 71-79.	2.5	69
65	in vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. International Journal of Cancer, 2000, 88, 652-657.	5.1	60
66	Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence fromin VitroStudies on Human Prostatic and Pancreatic Cancers¹. Endocrinology, 2000, 141, 2120-2128.	2.8	54
67	RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3509-3512.	3.6	43
68	High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2564-2571.	3.6	65
69	The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regulatory Peptides, 2000, 90, 77-84.	1.9	76
70	HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. Journal of Urology, 2000, 163, 623-629.	0.4	161
71	in vivo inhibition of PCâ€3 human androgenâ€independent prostate cancer by a targeted cytotoxic bombesin analogue, ANâ€215. International Journal of Cancer, 2000, 88, 652-657.	5.1	1
72	Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers. Endocrinology, 2000, 141, 2120-2128.	2.8	29

#	Article	IF	Citations
73	Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. Journal of Cancer Research and Clinical Oncology, 1999, 125, 444-452.	2.5	39
74	Targeted cytotoxic analog of luteinizing hormoneâ€“releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. American Journal of Obstetrics and Gynecology, 1999, 180, 1095-1103.	1.3	41
75	Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. , 1999, 85, 2608-2615.		26
76	Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. , 1999, 82, 592-598.		39
77	Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Letters, 1999, 136, 129-136.	7.2	46
78	Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer, 1998, 82, 909-917.	4.1	32
79	Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer, 1998, 83, 1335-1343.	4.1	54
80	New analogs of human growth hormoneâ€releasing hormone (1â€29) with high and prolonged antagonistic activity. Chemical Biology and Drug Design, 1998, 51, 134-141.	1.1	8
81	Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs, 1997, 8, 974-987.	1.4	23
82	Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. , 1997, 32, 164-172.		54
83	Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Research and Treatment, 1996, 40, 129-139.	2.5	11
84	Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. , 1996, 65, 870-874.		23
85	Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. International Journal of Cancer, 1994, 57, 574-580.	5.1	78
86	Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer. International Journal of Cancer, 1994, 59, 51-55.	5.1	38
87	Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. Journal of Cancer Research and Clinical Oncology, 1994, 120, 519-528.	2.5	47
88	Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Letters, 1994, 85, 111-118.	7.2	32
89	Inhibitory Effects of Antagonists of Bombesin/Gastrin Releasing Peptide (GRP) and Somatostatin Analog (RC-160) on Growth of HT-29 Human Colon Cancers in Nude Mice. Acta OncolÃ³gica, 1994, 33, 693-701.	1.8	50
90	Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormoneâ€“releasing hormone in the treatment of experimental prostate cancer. Cancer, 1993, 72, 3263-3270.	4.1	16

#	ARTICLE	IF	CITATIONS
91	Effect of bombesin, gastrin-releasing peptide (GRP)(14â€“27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. International Journal of Cancer, 1993, 54, 282-289.	5.1	42
92	Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. International Journal of Cancer, 1993, 55, 963-967.	5.1	71
93	Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate, 1993, 23, 165-178.	2.3	27
94	Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Letters, 1993, 71, 189-196.	7.2	52
95	Growth Inhibition of Estrogen-Dependent and Estrogen-Independent MXT Mammary Cancers in Mice by the Bombesin and Gastrin-Releasing Peptide Antagonist RC-3095. Journal of the National Cancer Institute, 1992, 84, 1915-1922.	6.3	60